We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

81 hedge funds and large institutions have $222M invested in AEON Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

11% more funds holding

Funds holding: 73 → 81 (+8)

8% more capital invested

Capital invested by funds: $205M → $222M (+$17.1M)

0.08% more ownership

Funds ownership: 1.09% → 1.17% (+0.08%)

Holders
81
Holders Change
+8
Holders Change %
+10.96%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
18
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.55M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$2.57M
3
Calamos Advisors
Calamos Advisors
Illinois
+$2.46M
4
MF
Magnetar Financial
Illinois
+$1.81M
5
WRBC
W.R. Berkley Corp
Connecticut
+$955K

Top Sellers

Rank Fund Capital Flow
1
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$3.43M
2
TCM
Tegean Capital Management
New York
-$491K
3
UOC
UBS O'Connor
Illinois
-$470K
4
Citigroup
Citigroup
New York
-$245K
5
OCAM
Owl Creek Asset Management
New York
-$245K
Name Holding Trade Value Shares
Change 		Change in
Stake
ECP
1
Empyrean Capital Partners
California
$13.8M – – –
Marshall Wace
2
Marshall Wace
United Kingdom
$13.1M – – –
DKCM
3
Davidson Kempner Capital Management
New York
$12.5M – – –
HSBC Holdings
4
HSBC Holdings
United Kingdom
$10.9M – – –
AC
5
Aristeia Capital
Connecticut
$10.1M – – –
RCM
6
Radcliffe Capital Management
Pennsylvania
$8.8M +$261K +369 +3%
PC
7
Periscope Capital
Ontario, Canada
$8.34M +$248K +350 +3%
SCM
8
Shaolin Capital Management
Florida
$7.98M – – –
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$7.84M – – –
Citadel Advisors
10
Citadel Advisors
Florida
$5.93M +$16.3K +23 +0.3%
LP
11
LMR Partners
United Kingdom
$5.91M – – –
Millennium Management
12
Millennium Management
New York
$5.73M +$152K +215 +3%
SCM
13
Saba Capital Management
New York
$5.41M – – –
Hudson Bay Capital Management
14
Hudson Bay Capital Management
Connecticut
$5.33M – – –
CH
15
CVI Holdings
Delaware
$5.08M – – –
FTCM
16
Fir Tree Capital Management
New York
$4.98M – – –
TCM
17
Tenor Capital Management
New York
$4.92M – – –
KIM
18
Karpus Investment Management
New York
$4.79M – – –
SC
19
Sculptor Capital
New York
$4.72M – – –
UOC
20
UBS O'Connor
Illinois
$4.68M -$470K -663 -9%
MF
21
Magnetar Financial
Illinois
$3.98M +$1.81M +2,549 +83%
Parallax Volatility Advisers
22
Parallax Volatility Advisers
California
$3.87M +$939K +1,326 +32%
Janus Henderson Group
23
Janus Henderson Group
United Kingdom
$3.57M +$2.57M +3,629 +259%
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$3.43M +$4.55M +6,429 New
FTCM
25
First Trust Capital Management
Illinois
$3.28M +$817K +1,154 +33%
1
2 3 4

AEON Hedge Fund Activity: Q3 2022 in Review

81 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2022, worth a combined $222M — up 8.3% from $205M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 3 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.55M. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $3.43M sold.

  • 81 institutional investors held AEON Biopharma (AEON) as of Q3 2022, up from 73 in Q2 2022.
  • Funds reported $222M of AEON Biopharma stock for Q3 2022, up 8.3% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q3 2022 and 5 closed out, a net change of +8 holders.
  • The largest AEON Biopharma buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.55M added.
  • The largest AEON Biopharma seller in Q3 2022 was Picton Mahoney Asset Management, an estimated $3.43M sold.

Based on aggregated 13F filings for Q3 2022.